In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents that leverage the human immune system to fight cancer, such as checkpoint inhibitors, vaccine-based ...

When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...

Scientists use multi-day live cell assays to monitor cell growth, viability, and cytotoxicity when evaluating the effects of drug treatment. However, maintaining consistent cell health over time ...

CAR-T-cell therapy has shown remarkable promise in addressing unmet medical needs in people with cancer. Continued progress in this field will depend, in part, on the advancement of frameworks for ...

Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

This article is based on a poster originally authored by Blaise Louis, Serena Belluschi, Daniel Weekes, Tom Mitchell, Holly Herbert, Tarun Vemulkar and Jeroen Verheyen, which was presented at ELRIG ...

Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...

Intravacc offers state-of-the-art analytical methods for identity, content, purity, structure, formulation, stability, and preclinical ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Universal, off‑the‑shelf CAR‑T cell therapies using gene‑edited donor T cells are beginning ...